Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypogonadotropic Hypogonadism Clear all
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced May 21, 2026, 11:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions
Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Effect of Treatment on Bone Mineral Density
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Rancho Cucamonga, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate (containing 300 mg T)
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
25 mg Androxal, Testim 1%
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced May 21, 2026, 11:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 11:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Genetic Disorder, Infertility, Hypogonadism, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Weeks to 120 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Interventions
Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
33
States / cities
Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions
Testosterone undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced May 21, 2026, 11:39 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced May 21, 2026, 11:39 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
5-day controlled metabolic dietary intake
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Kisspeptin 112-121, Naloxone, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypogonadism
Interventions
Nasobol®, Androderm® (Positive Control)
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, AndroGel, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced May 21, 2026, 11:39 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Endocrine Disease, Infertility, Hypogonadism, Amenorrhea, Adolescents
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
14 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 11:39 PM EDT